Jefferies analyst Brandon Couillard raised his price target for Danaher to $140 saying the company’s acquisition of GE’s Biopharma business “marks the capital deployment event investors have been waiting for.” The analyst views the deal as a “perfect fit” for Danaher that will solidify its leadership in bioprocessing, which he sees as the one of the best secular growth areas in all of healthcare. Couillard keeps a Buy rating on Danaher.
https://thefly.com/landingPageNews.php?id=2870347
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.